Why 40% of GLP-1 Users Quit for Reasons Beyond Cost

For months, the national conversation around GLP-1 drugs has focused on one question: can anyone afford to stay on them long enough to see results? It’s a valid concern. Medications like semaglutide and tirzepatide have transformed obesity care, but their…









